Skip to content

About us

IniTium is the latin word for beginning, Initiation. IniXium was created in 2014 as a customer-centric contract research organization (CRO) providing crucial knowledge-based expertise in structural biology at the initial stages of drug discovery to the biotech and pharmaceutical industry worldwide. We understand the needs of the sector for productivity, speed, reliability, and profitability, and value high quality, fast and professional industry grade research services for the best interest of the customer.  Our culture of excellence is one that is truly collaborative and sincerely altruistic.  We are committed to serving you, totally dedicated to your project, and keep your programs in permanent stealth mode when it comes to confidentiality.

Our Vision

  • Our vision is to build a strong and trustworthy organization towards which every drug hunter will be attracted to for rapid and reliable data at the discovery phases of their projects
  • We envision an organization where the dedication to the success of the customer’s program is the main driving force

Our Mission

  • Our mission is to contribute to the acceleration of the drug discovery process by using x-ray crystallography as our core technology
  • We want to establish strong collaborative interactions, and trustworthy relationships with our customers to achieve unparalleled success
  • Our creative team will always provide high quality and reliable data to guide you on the path to success


René Coulombe, M.Sc.

Co-founder and Senior Director of Structural Biology with over 25 years of experience in academic and industrial settings. René has setup the X-ray crystallography lab at Boehringer Ingelheim Canada Ltd, and participated in numerous drug discovery projects on several therapeutic targets.

James Féthière, Ph.D.

Co-founder and Senior Director of Protein Sciences with over 25 years of experience in protein chemistry and crystallography. Prior to founding IniXium, James setup and managed the protein and antibody production facility at IRIC in Montreal. Before that he was a membrane protein scientist at EMBL and M-Phasys GmbH in Germany